Abstract Temozolomide (TMZ) is the standard of care for patients with newly diagnosed glioblastoma (GBM) as well as those with recurrent anaplastic glioma (AG) and GBM. It has become common practice to re-expose patients to TMZ who had been previously treated with TMZ, or to switch patients to alternative dosing regimens of TMZ when there are signs of relapse or progress on standard TMZ therapeutic regimens. To date, however, there is a scarcity of data on the efficacy of this therapeutic strategy, currently referred to as TMZ rechallenge. We have conducted a retrospective review of patients with recurrent glioma rechallenged with TMZ. Patients experiencing progressive disease (PD) during TMZ therapy who were rechallenged with alternative TMZ regimens and patients rechallenged after stable disease in a TMZ-free interval were evaluated separately. A total of 90 rechallenges were identified in 80 patients. The progression-free survival at 6 months (PFS-6) was 48% in patients with AG (12/25) and 27.7% in those with GBM (14/47). The PFS-6 was 16.7% in AG and 26.3% in GBM for patients switched during TMZ and 57.9 and 28.6% in patients rechallenged after a TMZ-free interval of at least 8 weeks. Relevant hematological toxicity (NCI-CTC grade 3-5) was observed in 22 of 90 rechallenges, and relevant non-hematological in ten of 90 rechallenges. Temozolomide was well tolerated and generated promising PFS-6 in patients who had previously failed TMZ, regardless if they progressed during TMZ treatment, or if they were rechallenged after a TMZ-free interval. These results suggest that the TMZ rechallenge strategy warrants further investigation in a prospective randomized trial.
Introduction
Temozolomide (TMZ) is the drug of choice in the first-line radio-chemotherapy of glioblastoma (GBM) [1] as well as in the salvage therapy in recurrent GBM [2] and anaplastic glioma (AG) [3] . Whereas other effective regimens as associated with cumulative toxicities that prevent the extension of chemotherapy beyond five to six cycles, no relevant cumulative toxicity has been reported in patients treated with up to 40 cycles of TMZ [4] . These data render TMZ a good candidate for long-term therapy, such as when the residual tumor persists after six cycles, or even for maintenance therapy in patients without a measurable tumor. It can be speculated that the use of TMZ could improve the 12-month progression-free survival (PFS) rate of 26.9% of the EORTC/NCIC trial in patients with newly diagnosed GBM [1] . In that trial, about 9 months (concomitant radio-chemotherapy and six cycles of adjuvant chemotherapy with TMZ) coincided with the end of chemotherapy. However, even after prolonged use of TMZ, all patients with high-grade gliomas eventually relapse. Although a large number of salvage therapies are used, with the approach depending upon the clinical setting, none of these regimens is established as a standard. In addition, due to its incorporation into the first-line treatment of GBM, TMZ is no longer considered by many investigators to be a reasonable choice for patients with recurrent GBM. However, alternative schedules of TMZ addressing different pathophysiological mechanisms could be effective even after progression during standard TMZ regimens (''TMZ failure rechallenge'') and for rechallenge after a TMZ-free interval (''TMZ-free interval rechallenge''). Therefore, there is an urgent clinical need to understand whether a rechallenge with TMZ, to date the most effective agent against gliomas, is active in patients with malignant gliomas. This issue has not been addressed in a larger series of patients.
Selection of the most promising regimen for this approach is currently based on limited data. The standard regimen of TMZ at 150-200 mg/m 2 body surface area on days 1-5 of a 28-day cycle [2, 3] is the best analyzed to date and may well be effective in patients who have progressed after a TMZ-free interval after initial stabilization of disease and termination of TMZ. However, if progression has occurred during therapy with TMZ, it would be unreasonable to continue TMZ at the same regimen, i.e. the same dose at the same intervals. Therefore, various dosing schedules that increase the duration of exposure and the cumulative dose of TMZ, are currently being investigated for the treatment of recurrent glioma, with the aim of enhancing antitumor activity and overcome resistance.
In addition, there may be a benefit from alternative modes of action than the presumable cytotoxicity associated with the standard dose, e.g. antiangiogenic properties of a metronomic regimen, 20 mg total/day [5] . A ''1 week on/1 week off'' scheme (150 mg/m 2 at days 1-7 and days 15-21, in a 28-day cycle) has been associated with considerable efficacy and was tolerated by patients [6, 7] . Another alternative is an intensified 3 out of 4 weeks approach (75-100 mg/m 2 at days 1-21, in a 28-day cycle). This regimen may yield similar results with respect to efficacy, but a higher rate of toxicity, specifically lymphopenia and infection, have been reported [8, 9] . The latter two regimens aim at a dose intensification that may have the result of enhancing the direct cytotoxic effect of TMZ and possibly depleting the DNA repair enzyme O 6 -methylguanine DNA methyltransferase (MGMT) [10] . This enzyme modulates resistance to alkylating chemotherapeutic agents [11] .
To date, two reports provide the first preliminary evidence of the potential efficacy of a TMZ rechallenge: in the first analysis, 14 patients with grade III or IV gliomas were rechallenged with 150-200 mg/m 2 TMZ in the standard schedule after progressing after an initial good response to TMZ [12] . The response rate (RR) was 29%, the stabilization rate 14%, and the median time to progression (mTTP) 14 weeks. In a series of 98 patients, with the ''1 week on/1 week off'' schedule in recurrent GBM, nine patients were treated with the standard dose TMZ at first line and were rechallenged with the dose-intense TMZ regimen at the time of first progression. Although the study arms comprised small numbers of patients, the outcome data of rechallenged patients did not differ compared to the whole group [6] .
Based on the hypothesis that TMZ rechallenge may salvage some patients with disease progression during or after TMZ therapy, we evaluated a dataset of 90 TMZ rechallenges in patients with malignant glioma in three institutions for the toxicity and efficacy of the therapeutic approach.
Methods

Study design and patients
A retrospective review of patients with recurrent glioma rechallenged with TMZ was performed in three institutions (Department of Neurology, University of Regensburg; Department of Neurology, University of Tübingen; Department of Neurooncology, University of Heidelberg, Germany). Patients with World Health Organization (WHO) grade III AG, anaplastic oligodendroglioma, and anaplastic oligoastrocytoma, or WHO grade IV GBM or gliosarcoma were included. Patients with grade II glioma (including astrocytoma, oligoastrocytoma, and oligodendroglioma) are reported for toxicity, but not for efficacy, because of the small numbers. Nine of the GBM patients were already included in a previous report [6] .
This analysis was compiled from study and individual treatment patients, in which patients had consented to participate. All clinical trials involved in the primary treatment of patients were conducted after full approval and in accordance with the ethical standards of the responsible institutional (IRB or EC) national or European authorities.
Treatment
Basic treatment guidelines for considering rechallenge were consistent at all three institutions: if patients relapsed more than 8 weeks after discontinuation of prior TMZ, they were treated with the same or an alternative regimen of TMZ; if they progressed while still receiving TMZ, they were treated with an alternative regimen. 
Evaluation of toxicity and efficacy
In order for a patient to be included in this analysis, a full range of prospectively documented data needed to be available for analysis: demographic data; data on histology, extent of resection, and radiotherapy in the first-line and relapse setting; data on all prior chemotherapy regimens with dose modifications, reasons for discontinuation, and responses; data on doses, regimens, number of cycles, and duration of treatment with TMZ in the first-line setting and at rechallenge; dates of diagnosis and progression under primary administration of TMZ and rechallenge; laboratory values, including full blood counts and C-reactive protein for the evaluation of hematological toxicity and infective complications. An effort was made to determine the outcome of all patients.
Toxicity was classified and graded using the National Cancer Institute Common Toxicity Criteria ver. 3.0 (NCI-CTC) score, focusing on grade 1-5 toxicities for leukopenia, lymphopenia, thrombocytopenia, infections, nausea, and vomiting and on grade 3-5 for other toxicities during treatment with TMZ. Response evaluation by magnetic resonance imaging (MRI) using T1, T1 plus gadolinium, and T2 or FLAIR sequences was performed using standard Macdonald's criteria for grade III and IV tumors [13] . Stable disease (SD) was defined as measurable stable disease or no progression after macroscopic complete resection.
Statistical analysis
All data were entered into a database and analyzed statistically using JMP ver. 7.0 (SAS, Cary, NC). The response rates, progression-free survival at 6 and 12 months (PFS-6/12), mTTP after rechallenge with TMZ, and median overall survival (mOS) from TMZ rechallenge are reported from primary TMZ and from diagnosis. The TTP was defined as the time from diagnosis or first day on TMZ as rechallenge, to the first signs of progression by MRI or clinical symptoms, whichever came first. The OS was defined as the time from diagnosis before first-line therapy until death. Survival data were calculated according to the Kaplan-Meier method. Data on patients with TMZ rechallenge at failure during TMZ (''TMZ failure rechallenge'') and rechallenge in a TMZ-free interval (''TMZfree interval rechallenge'') were evaluated both pooled and separately.
Results
Data collection and number of patients
All data were collected from patients (n = 80) with grade II, III, or IV gliomas who met the criteria of having a complete data set available and having had at least one course of prior TMZ. All patients were treated between January 2000 and October 2007. Some patients received a rechallenge of TMZ more than once, so a total of 90 TMZ rechallenges were included. Thirteen patients had grade II gliomas, 22 had grade III and 45 grade IV. Seven of the grade II (50%) and 12 of the grade III tumors (55%) harbored an oligodendroglial component.
Demographic data
The median age of all patients was 48 years (41 years for grade III tumors and 52 years for grade IV tumors; range 19-69 years). At rechallenge, the mean numbers of previous resections and radiotherapies were two (range 1-4) and one (range 1-3), respectively, and the median Karnofsky Performance Score (KPS) was 90 (range 30-100). Notably, 32% of the AG patients and 15% of GBM patients had a non-TMZ based salvage therapy between the first and second (rechallenge) treatment with TMZ.
At rechallenge, patients received one of five TMZ regimens: 75 mg/m 2 /day at days 1-42 during radiotherapy plus 150-200 mg/m 2 /day at 5/28 days (n = 1); 150-200 mg/m 2 /day at 5/28 days (n = 43); 150 mg/m 2 /day at 7/14 days (n = 33); 75 mg/m 2 /day at 21/28 days (n = 5); continuous metronomic 40 mg/day (n = 8). Of the 90 (88%) rechallenge regimens, 79 consisted of a TMZ monotherapy. Eleven patients received TMZ combinations with 13-cis retinoic acid (n = 5) or PEG-liposomal doxorubicin (n = 6). Rechallenges with combinations of TMZ with radiotherapy (n = 1), 13-cis retinoic acid (n = 5), and PEG-liposomal doxorubicin (n = 6) were kept within the analysis as the numbers were low, and their TTP and OS were within the range of the respective entity group.
Toxicity
All TMZ cycles for all patients treated at recurrence were assessed for toxicity. All TMZ-based regimens were well tolerated at rechallenge. There were no hematological or non-hematological grade 5 toxicities. Toxicity in patients treated with the 40 mg/day continuous schedule (n = 8) did not exceed grade 2. The dose-intense schedules had a comparable distribution of grade 1-4 toxicities ( Table 1) . In addition to the adverse events shown in Table 1 , diarrhoea, vertigo, taste alteration, constipation, meteorism, pruritus or transaminase elevation not exceeding grade 2 were noted in one patient each.
Severe adverse events, defined as death, hospitalization or a grade 3/4 event with a ''likely'' attribution to TMZ, occurred in six patients, with an average of 0.3 events per patient over the treatment course. These events were attributable to the known bone marrow toxicity of TMZ or related problems (infection). One patient experienced a pulmonary embolism. Patients with grade IV gliomas experienced a higher rate of severe adverse events, possibly related to the more malignant clinical course of disease in these patients.
Therapy terminations
Primary TMZ was stopped due to tumor progression (n = 30), end of a clinical study (n = 24), patient request (n = 13), or toxicity (n = 9); five patients completed an individual treatment regimen as planned.
Termination of TMZ rechallenge was due to toxicity (n = 6/72, 8%), patient's decision (n = 6, 8%), end of study (n = 3, 4%), or tumor progression (n = 44, 61%) ( Table 2) .
Efficacy
Outcomes after first-line treatment of TMZ in this group of patients were favorable. Response rates [defined as clinical response (CR) or partial responses (PR)], were 55% in grade III and 10% in grade IV gliomas; 32 and 62% of the patients experienced SD. The mTTP was 77 weeks for grade III and 41 weeks for grade IV gliomas. Of note, only two patients in the grade III (2.1 and 3.6 months) and three patients in the grade IV glioma group (1.4, 3.9, and 3.9 months) had an early progression on the first TMZ treatment.
Before TMZ rechallenge, 57 patients received macroscopic complete or partial resections. Upon TMZ rechallenge, the RR was 32% in patients with grade III and 10.4% in patients with grade IV gliomas, and the rates of SD were 36 and 58.3%. The PFS-6 was 48% for patients with grade III and 27.7% for patients with grade IV gliomas; the respective values for the patients with ''TMZ failure rechallenge'' were 16.7% (AG) and 26.3% (GBM), and for ''TMZ-free interval rechallenge'', 57.9% (AG) and 28.6% (GBM). There was a significantly better outcome in TTP (v 2 , Wilcoxon test, P = 0.0473) in the grade III gliomas retreated after a TMZ-free break ( Fig. 1; Table 3 ). The respective data were not different in the grade IV gliomas between the subgroups (TTP, v 2 , Wilcoxon test, P = 0.2706) ( Fig. 2; Table 3 ). Importantly, no difference was observed for GBM patients on primary TMZ for B6 or [6 months in the ''TMZ-failure'' group (data not shown).
The mOS from primary TMZ was 79.0 weeks for GBM and 180.1 weeks for AG; the mOS from diagnosis was 100.3 weeks for GBM and 289.9 weeks for AG. Interestingly, there was also an association of the timepoint of rechallenge with OS. In grade III gliomas, OS from rechallenge was significantly better in the subgroup of patients rechallenged after a TMZ-free break (v 2 , Wilcoxon test, P = 0.0011) ( Table 3) .
Comparing patients with GBM rechallenged at 150-200 mg/m 2 /day at 5/28 days (n = 15) after a TMZ-free interval of at least 8 weeks or 150 mg/m 2 /day at 7/14 days (n = 26) in the group progressing under TMZ, the mTTP was 24 and 22 weeks, which is not a relevant difference in these cohorts. The patient numbers in the other regimens were too small to compare.
For the subset of grade III tumors with an oligodendroglial component, the PFS-6 was 58.3%, and mTTP upon TMZ rechallenge was 38.6 weeks. It is important to note that these patients survived 87.9 weeks beyond TMZ rechallenge.
Discussion
Rechallenge is defined as the re-use of a therapeutic agent that had been used previously in the same patient. Rechallenge with TMZ is promising as the agent can be used in different heterogenous regimens, likely showing no cumulative toxicity. We have demonstrated that a rechallenge with TMZ in patients with malignant gliomas is feasible and yields promising response rates, stabilizations, and clinically meaningful prolongation of progression-free intervals, both for rechallenges with alternative regimens of TMZ if the patient relapsed during TMZ treatment, and for rechallenges in a TMZfree treatment period. To circumvent the issue of pseudoprogression, best defined as apparent radiographic disease progression immediately or within 3 months after a given (radiotherapy-containing) treatment that resolves without altering the treatment to stable or improved MRI [14] , patients were preferably included in the study not earlier than 3 months after the initiation of the prior TMZ treatments. Two patients included at \2 months received a re-biopsy to confirm progressive disease. An additional three patients included \4 months from initiation of prior TMZ are responding similarly as the overall cohort.
The toxicity induced by TMZ rechallenge was in the range of the published primary and relapse TMZ data, which was in line with clinical experience that TMZ has probably no cumulative toxicity (Table 1) [1] [2] [3] . In addition, no secondary malignancies were reported in our cohort. In a subset of approximately 7% of patients, treatment was terminated because of toxicity. The discontinuation rates were comparable in the primary and rechallenge setting, which also emphasizes the absence of cumulative toxicity of TMZ.
Patients with high-grade gliomas responded unexpectedly well, with response rates of 32 and 10.4% in patients with grade III and grade IV gliomas. The PFS-6 was 48 and 27.7%, and mTTP was 25.7 and 20.4 weeks. When subgroups are compared, the results in tumors with an oligodendroglial component are, as expected, more promising than those in non-oligodendroglial tumors.
To substantiate possible differences in the efficacy of rechallenges in patients who progressed under treatment with TMZ (''TMZ-failure rechallenge'') and patients who progressed after termination of primary TMZ in a TMZ- Fig. 1 Progression-free survival in the 25 rechallenges in grade III gliomas according to ''TMZ-failure rechallenge'' (red) and ''TMZfree interval rechallenge'' (blue). Confidence intervals at the 95% level are depicted by the broken lines. TMZ Temozolomide free treatment interval (''TMZ-free interval rechallenge''), we evaluated these subgroups separately. A remarkable difference was seen only in those patients with grade III gliomas for mTTP, PFS-6 and -12, and mOS (Table 3 ; Fig. 1 ). For the larger group of GBM patients, no relevant differences between these two groups were detected. It is therefore tempting to speculate that our hypothesis-to use an alternative regimen in the TMZ-failure rechallenges to provide a meaningful efficacy of the TMZ rescue regimen-might be correct. This argues for an equal efficacy of TMZ rechallenge in both situations in GBM, provided that alternative regimens of TMZ are used in patients progressive under TMZ treatment. The significant difference in OS from rechallenge in grade III gliomas is most likely due to the TMZ rechallenge.
Months Cumulative Proportion Surviving
Recognizing the retrospective nature and lack of a control group in these data, the efficacy none-the-less suggests that TMZ rechallenge is comparable with data from relapse trials utilizing different chemotherapy regimens. In a study reported by Yung et al. [2] , the response rate for TMZ in the relapse of GBM was 5.4%, the rate of stabilizations was 40.2%, and the PFS-6 was 21%; in comparison, in our cohort, these values were 10.4, 58.3%, and 27%, respectively. Of note, 65% of the patients in that trial [2] had been preexposed to nitrosoureas [2] . The favorable outcome in Fig. 2 Progression-free survival in the 47 rechallenges in grade IV gliomas according to ''TMZ-failure rechallenge'' (red) and ''TMZfree interval rechallenge) (blue). Confidence intervals at the 95% level are depicted by the broken lines our patient population may be due to the implementation of dose-intense TMZ regimens as opposed to the standard 5/ 28 days regimen. The efficacy of alternative regimens, such as the ''1 week on/1 week off'' regimen, is further substantiated by data, which suggest considerable efficacy of this regimen in recurrent GBM [6] . We have previously reported a PFS-6 of 44% in patients with relapse of highgrade gliomas who were not pretreated with TMZ in the majority of cases. However, in patients with a TMZ-free interval rechallenge, the efficacy of the TMZ rechallenge appeared not to differ between the approved 5/28 days regimen [2] versus the ''1 week on/1 week off'' regimen [6] .
In 1999, a meta-analysis by Wong et al. [15] reported an overall RR of 6% and a PFS-6 of 15% in patients with recurrent GBM. A comparison of our data to this benchmark meta-analysis suggests that our data warrant further substantiation in a randomized clinical trial. Patients with AG in that meta-analysis experienced a response rate of 14%, stabilizations of 48%, and PFS-6 of 48%, which is in the range of our findings (32, 36 and 48%, respectively). This is also the case for the PFS-6 of 46% reported in the trial leading to approval in AG [6] .
We considered the retrospective nature of these data, a potential selection bias, and the overall favorable median age (52 years) in the GBM cohort, which is slightly below the average, for this rechallenge patient population. Thus, in order to minimize biases, all consecutive patients treated within our institutions were included in the analyses, and a thorough review of the patients' original charts was undertaken. In addition, a recently published study defined prognostic groups in patients with relapse of high-grade glioma by means of a recursive partitioning analysis [16] . If the GBM patients from our evaluation were introduced according to their prognostic factors into this analysis, they should reach a mOS of 5.6-6.4 months; patients with grade III gliomas should reach a mOS of about 17 months. Considering that 32% of the grade III and 16% of our GBM patients were in second relapse at TMZ rechallenge, the outcomes in our cohort with a mOS from rechallenge of 16.7 and 5.9 months after TMZ rechallenge, is well within the expected range.
The Canadian RESCUE study evaluates the concept of TMZ rechallenge with an alternative regimen of TMZ (28/ 28 days) after failure of primary TMZ. In this study, an effort was made to construct three groups of patients that underwent rechallenge. Two groups are similar to our ''TMZ-failure'' and ''TMZ-free rechallenge'' groups. The PFS-6 rates of the RESCUE population are 23 and 35% as compared to 26.3 and 28.6% in our series. However, Perry et al. [17] also defined a third group of patients that are a subgroup of the TMZ failure group with a primary TMZ exposure of more than 6 months. The latter group did poorly, with a PFS-6 of only 7%.
The results of our study justify the initiation of a prospective, controlled trial analyzing rechallenge with intensified TMZ regimens in patients who progress while on TMZ therapy, or who progress after discontinuation of TMZ treatment. They also indicate a role for rechallenge in a defined subset of patients without other approved options or experimental protocols.
